On Dec 03, major Wall Street analysts update their ratings for $Merus (MRUS.US)$, with price targets ranging from $67 to $100.
TD Cowen analyst Tara Bancroft maintains with a buy rating.
Needham analyst Ami Fadia maintains with a buy rating, and maintains the target price at $85.
Truist Financial analyst Asthika Goonewardene maintains with a buy rating.
CCORF analyst John Newman maintains with a buy rating, and maintains the target price at $67.
LifeSci Capital analyst Charles Zhu maintains with a buy rating, and maintains the target price at $100.
Furthermore, according to the comprehensive report, the opinions of $Merus (MRUS.US)$'s main analysts recently are as follows:
Following an announcement that Merus has entered an exclusive licensing agreement with Partner Therapeutics for the commercialization of zenocutuzumab in the treatment of NRG1 fusion-positive cancer in the U.S., an update has been made to the financial model to account for this new development.
Here are the latest investment ratings and price targets for $Merus (MRUS.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
